Kinase gene fusions in defined subsets of melanoma

Genomic rearrangements resulting in activating kinase fusions have been increasingly described in a number of cancers including malignant melanoma, but their frequency in specific melanoma subtypes has not been reported. We used break‐apart fluorescence in situ hybridization (FISH) to identify genomic rearrangements in tissues from 59 patients with various types of malignant melanoma including acral lentiginous, mucosal, superficial spreading, and nodular. We identified four genomic rearrangements involving the genes BRAF, RET, and ROS1. Of these, three were confirmed by Immunohistochemistry (IHC) or sequencing and one was found to be an ARMC10‐BRAF fusion that has not been previously reported in melanoma. These fusions occurred in different subtypes of melanoma but all in tumors lacking known driver mutations. Our data suggest gene fusions are more common than previously thought and should be further explored particularly in melanomas lacking known driver mutations.

[1]  I. Yeh,et al.  Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion , 2015, Pigment cell & melanoma research.

[2]  B. Bastian,et al.  From melanocytes to melanomas , 2016, Nature Reviews Cancer.

[3]  J. Reis-Filho,et al.  High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform , 2011, Laboratory Investigation.

[4]  I. McLean,et al.  Uveal melanoma , 1997, Cancer.

[5]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[6]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[7]  F. Cappuzzo,et al.  Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[8]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[9]  D. Morton,et al.  Surgery for distant melanoma metastasis. , 2012, Cancer journal.

[10]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[11]  K. Tsuta,et al.  BRAF V600 mutations and pathological features in Japanese melanoma patients , 2014, Melanoma research.

[12]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[13]  Kazuhiro Takahashi,et al.  BRAF point mutations in primary melanoma show different prevalences by subtype. , 2004, The Journal of investigative dermatology.

[14]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[15]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[16]  Iwei Yeh,et al.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.

[17]  P. Jänne,et al.  Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease , 2014, PloS one.

[18]  Subhajyoti De,et al.  IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples , 2016, J. Am. Medical Informatics Assoc..

[19]  Junfeng Xia,et al.  Cancer Biology and Signal Transduction a Meta-analysis of Somatic Mutations from next Generation Sequencing of 241 Melanomas: a Road Map for the Study of Genes with Potential Clinical Relevance , 2022 .

[20]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[21]  A. Gown,et al.  Quality control in immunohistochemistry. Report of a workshop sponsored by the Biological Stain Commission. , 1989, American journal of clinical pathology.

[22]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.

[23]  Frank McCormick,et al.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.

[24]  P. Stephens,et al.  BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition , 2013, Clinical Cancer Research.

[25]  Jason Wang,et al.  The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Gene Rearrangement in Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[26]  V. Schabert,et al.  Comparative healthcare costs in patients with metastatic melanoma in the USA , 2015, Melanoma research.

[27]  A R Forrest,et al.  Quality control. , 1978, British medical journal.

[28]  Caroline Robert,et al.  Safety and efficacy of vemurafenib in BRAF V 600 E and BRAF V 600 K mutation-positive melanoma ( BRIM-3 ) : extended follow-up of a phase 3 , randomised , open-label study , 2015 .

[29]  F. Schmidt Meta-Analysis , 2008 .

[30]  Arun D. Singh,et al.  Uveal melanoma: trends in incidence, treatment, and survival. , 2011, Ophthalmology.

[31]  R. Scolyer,et al.  Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma , 2009, Oncogene.

[32]  Iwei Yeh,et al.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.

[33]  J. Choi,et al.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.

[34]  D. Whiteman,et al.  Anatomic site, sun exposure, and risk of cutaneous melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Lauren E Haydu,et al.  Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.

[36]  L. Thomas,et al.  Acral lentiginous melanoma: histopathological prognostic features of 121 cases , 2007, The British journal of dermatology.

[37]  J. Q. Rosso,et al.  Acral Lentiginous Melanoma: Incidence and Survival Patterns in the United States, 1986-2005 , 2010 .

[38]  N. Lu,et al.  Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Wei Li,et al.  Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas , 2013, Pigment cell & melanoma research.

[40]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[41]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[42]  I. Yeh,et al.  Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors , 2015, Nature Communications.

[43]  M. Dimon,et al.  An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples , 2015, PloS one.

[44]  J. Bulliard,et al.  Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  F. Hirsch,et al.  ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer , 2014, Clinical lung cancer.

[46]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[47]  Y. Chan,et al.  Expression of Trk receptors in otolith-related neurons in the vestibular nucleus of rats , 2005, Brain Research.

[48]  Kai Wang,et al.  The distribution of BRAF gene fusions in solid tumors and response to targeted therapy , 2015, International journal of cancer.

[49]  L. Hirst,et al.  Ultraviolet light exposure as a risk factor for ocular melanoma in Queensland, Australia , 2000, Ophthalmic epidemiology.

[50]  Targeted therapy in leukemia , 2008, Modern Pathology.

[51]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[52]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.